Thursday, June 11, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 48 of 1,261
  1. US 12280124

    Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  2. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  3. US 12280057

    Vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing

    SOUTH DAKOTA BOARD OF REGENTS · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  4. US 12280089

    Dry powder formulation of caveolin-1 peptides and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  5. US 12280122

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  6. US 12280063

    Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  7. US 12280055

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  8. US 12279630

    Treatment and prevention of seed allergies

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  9. US 12280113

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  10. US 12280120

    Tumor-specific cleavable linkers

    Xilio Development, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  11. US 12281073

    Substituted piperidine compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  12. US 12281021

    System and method for making boron oxide nanoparticles

    The Regents of the University of California · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  13. US 2025120959

    NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE

    BIOPROJET PHARMA [FR] · Granted Apr 17, 2025 · Expires Apr 12, 2045

    granted
  14. WO 2025077836

    LIPIDES IONISABLES ET NANOPARTICULES LIPIDIQUES POUR ADMINISTRATION D'ARN

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 17, 2025 · Expires Apr 12, 2045

    granted
  15. WO 2025078995

    COMPOSÉS DE 6-(PYRIMIDIN-4-YL)QUINOLÉINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASE DÉPENDANTE DE LA CYCLINE

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 17, 2025 · Expires Apr 12, 2045

    granted
  16. TW 202515875

    Solid forms comprising a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 16, 2025 · Expires Apr 11, 2045

    granted
  17. TW 202515903

    Anti-PD-1-based treatment before and after surgery

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 16, 2025 · Expires Apr 11, 2045

    granted
  18. US 12275964

    Variant type V CRISPR/Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  19. US 12275937

    Stereospecific linkages in RNA editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  20. US 12275957

    Next generation designer liver organoids and their methods of preparation and use

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  21. US 12275966

    Genetically engineered cells

    The Regents of the University of California · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  22. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  23. US 12275684

    Methods for making and using endoxifen

    ATOSSA THERAPEUTICS, INC. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  24. US 12275685

    Oligo-benzamide analogs and their use in cancer treatment

    The Board of Regents of the University of Texas System · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.